Partner Headlines - LLY

  1. Thursday Morning Earnings Reports

    Benzinga
  2. Earnings Scheduled For July 24, 2014

    Benzinga
  3. New Study Shows Beta-Amyloid Imaging Is Associated With Altered ...

    Benzinga
  4. Lilly And Immunocore Enter Immunotherapy Agreement To Co-Discover ...

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. US Stock Futures Mostly Higher Ahead Of Goldman Sachs Earnings

    Benzinga
  7. Barclays Downgrades Pharmaceutical Sector

    Benzinga
  8. UPDATE: Barclays Upgrades Eli Lilly Despite Sector Downgrade

    Benzinga
  9. Benzinga's Top Upgrades

    Benzinga
  10. Eli Lilly is on the Right Track

    GuruFocus
  11. Celgene Sees Better Results For Psoriatic Arthritis

    IBD
  12. Eli Lilly Bets Big on Diabetes, Cancer Drugs

    FoxBusiness
  13. Novo Nordisk Raises Insulin Prices As Demand Grows

    IBD
  14. ASCO Meeting Day 3: Do More Treatments Equal A Longer Life?

    Benzinga
  15. ASCO Meeting Day 2: 'Promising' Results From JNJ's Imbruvica ...

    Benzinga
  16. John Paulson's 4 Stocks Trading for Less Than He Paid for Them

    GuruFocus
  17. Lilly Says Abemaciclib in Phase 1 Study Demonstrated Single-Agent ...

    Benzinga
  18. Eli Lilly insulin trial succeeds

    IBD
  19. Cross-Border Megamergers Drive Global Takeover Boom

    IBD
  20. Google Celebrates Dorothy Hodgkin & Her Contributions To Chemistry

    Benzinga
  21. Eli Lilly's Basal Insulin Outperforms Lantus In Trial

    IBD
  22. UPDATE: Eli Lilly Announces Peglispro Shows Superiority Compared ...

    Benzinga
  23. Can Pfizer Make Up Its Loss?

    GuruFocus
  24. Merck Sells Consumer Unit To Bayer To Focus On R&D

    IBD
  25. Bayer Buys Merck Consumer Care Unit

    FoxBusiness
  26. Will Pfizer's Q1 2014 Earnings Beat the Street on May 5, 2014?

    GuruFocus
  27. AstraZeneca Rejects Pfizer's $106B Buyout Bid

    FoxBusiness
  28. Novo Nordisk Struggles In U.S. Market; Q1 Sales Miss

    IBD
  29. Novo Nordisk Q1 Revenue Misses; Guidance Lowered

    IBD
  30. Vanguard Health Care Fund's Top Quarterly Holdings

    GuruFocus
  31. Actavis Earns Over-The-Top Q1

    IBD
  32. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  33. Actavis Q1 Earnings Beat On Generic Cymbalta Surprise

    IBD
  34. China Rule Change Further Opens Yuan To World Markets

    IBD
  35. These Three Pharmaceutical Companies Shake The Market With Their ...

    GuruFocus
  36. Drugmakers' Q1 was anemic

    IBD
  37. Eli Lilly Jr. Made His Firm A Pharmaceutical Power

    IBD
  38. Earnings Scheduled For April 24, 2014

    Benzinga
  39. Big Pharmas Swap Specialties

    IBD
  40. Drugmakers Prod European Stocks To Post-Easter Rally

    IBD
  41. Benzinga's M&A Chatter for Tuesday April 22, 2014

    Benzinga
  42. Novartis, Glaxo Swap Units; Valeant Bids For Allergan

    IBD
  43. Stocks Rise In Higher Volume; Gilead Up After Hours

    IBD
  44. Pharma Deal Frenzy: A Bid to Boost Profits, Cut Risk

    FoxBusiness
  45. Amgen Slumps After 1Q Earnings Miss

    FoxBusiness
  46. Novartis, Glaxo Swap Units; Lilly Buying Animal Biz

    IBD
  47. Stock Futures Mixed And Busy; Allergan, Netflix, Glaxo Climb

    IBD
  48. Novartis Announces Multi-Billion-Dollar Revamp

    FoxBusiness
  49. US Stock Futures Edge Higher Ahead Of McDonald's Earnings

    Benzinga
  50. Stock Futures Steady Amid Raft of Health M&A

    FoxBusiness
  51. Wall Street Ticks Up as Traders Parse News Deluge

    FoxBusiness
  52. ELI LILLY

    IBD
  53. No Legwork Mondays – Takeda, Eli Lilly, And Actos

    Benzinga
  54. Market Wrap For April 14: Markets Surge on Positive Retail Data, ...

    Benzinga
  55. Lilly, Takeda must pay $9 bil

    IBD
  56. Ethical Drug Stocks Are Struggling

    IBD
  57. UPDATE: BMO Capital Upgrades Eli Lilly

    Benzinga
  58. Takeda, Lilly to 'Vigorously Challenge' Actos Ruling

    FoxBusiness
  59. Benzinga's Top Upgrades

    Benzinga
  60. Takeda Responds to $6B Verdict in Diabetes Drug Case

    Benzinga
  61. Top 4 NYSE Stocks In The Drug Manufacturers-Major Industry With ...

    Benzinga
  62. Pfizer Breast-Cancer Drug Scores, But Street Cautious

    IBD
  63. Market Wrap For April 3: Markets Winning Streak Fails To Extend ...

    Benzinga
  64. Wide Moat Stocks: Protection In A Correction

    YCharts
  65. UPDATE: Cowen & Company Upgrades Eli Lilly

    Benzinga
  66. Benzinga's Top Upgrades

    Benzinga
  67. Biotech Auxilium Boosts Position In Men's Health Care

    IBD
  68. Lilly Expands Generic Deal With Prasco

    FoxBusiness
  69. UPDATE: Bank of America Reiterates on Eli Lilly and Co. Following ...

    Benzinga
  70. Merck Snags Baxter Executive As CFO

    FoxBusiness
  71. Box, Online Storage Service Provider, Files For IPO

    IBD
  72. Which Pharmas Can Keep Up Dividend-Buybacks?

    YCharts
  73. Forest Laboratories' Recovery

    GuruFocus
  74. Pfizer Breast-Cancer Drug To Show If It's For Real

    IBD
  75. Pharma Patent Cliff: Why Worst Seems Over

    YCharts
  76. Elanco Announces Agreement to Acquire Lohmann Animal Health; ...

    Benzinga
  77. Actavis Q4 Beats Street; Guidance Affirmed For Now

    IBD
  78. Eli Lilly up on lung cancer trial

    IBD
  79. Market Wrap For February 19: Stocks Close Lower, Nasdaq Ends ...

    Benzinga
  80. Lilly Drug Ramucirumab Boosts Lung Cancer Survival

    IBD
  81. Stocks Stage Quiet, Mixed Open; Eli Lilly Up, U.S. Steel Tanks

    IBD
  82. Actavis, Valeant, Jazz: New Roles For Specialty Pharma

    IBD
  83. #PreMarket Primer: Friday, January 31: Emerging Market Turmoil ...

    Benzinga
  84. Eli Lilly

    IBD
  85. Market Wrap For January 30: Markets Focus on Good News

    Benzinga
  86. Lilly's Cymbalta to Trigger 'Severe' Sales Slide

    FoxBusiness
  87. UPDATE: Eli Lilly Posts Drop In Q4 Profit

    Benzinga
  88. #PreMarket Primer: Thursday, January 30: Fed Cut Stimulus By ...

    Benzinga
  89. Tug Of War In Ariad Pharmaceuticals

    Benzinga
  90. Benzinga's M&A Chatter for Monday January 27, 2014

    Benzinga
  91. Income + Value Investing: YCharts Sector Report

    YCharts
  92. Benzinga Weekly Preview: Tech Sector To Steal The Spotlight

    Benzinga
  93. Ariad Shares Continue to Surge Amidst Buyout Rumors

    Benzinga
  94. Is The Market On Drugs?

    Benzinga
  95. AstraZeneca: Time to Make a Bet? Steven Cohen Seems to Think ...

    GuruFocus
  96. Wide Moat Stocks Against Two Value Systems

    YCharts
  97. Biogen, Celgene Lead 5 Top Large-Cap Drugmakers

    IBD
  98. Lilly Acquires CGRP Antibody for Migraine Prevention from Arteaus ...

    Benzinga
  99. Bulls Charge the Street: S&P Snaps 3-Day Losing Streak

    FoxBusiness
  100. Celgene Gets Good News On Two Cancer Drugs; Stock Up

    IBD
Trading Center